BioSpace News Archive

Business

Baxter Announces Preliminary Net Sales for the Fourth-Quarter and Full-Year 2019 and Announces Preliminary Full-Year 2020 Guidance

Baxter International Inc. announced preliminary net sales for the quarter and full year ended December 31, 2019, and preliminary full-year 2020 guidance for select financial metrics.

January 12, 2020
·
16 min read
Biotech Bay

Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outlook

OPTIC phase 1 trial progressing with plans to complete patient dosing in cohort three, begin enrollment in cohort four in 1Q20

January 12, 2020
·
6 min read
Business

NanoString Provides Preliminary Operational and Financial Results for Fourth Quarter and FY 2019

FY19 Product and Service Revenue of $103.7 million, including GeoMx DSP Revenue of $10.8 million, Exceeds High End of Guidance Ranges

January 12, 2020
·
6 min read
Business

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones

INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $238 Million with Approximately 42,100 TRx

January 12, 2020
·
10 min read
Business

Cutera Announces Preliminary Financial Results for Fourth Quarter and Full-Year 2019

Cutera, Inc., a leading provider of energy-based aesthetic systems for practitioners worldwide, announced certain preliminary, unaudited, financial results for the fourth quarter and year ended December 31, 2019.

January 12, 2020
·
3 min read
Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant unmet medical needs, will provide an outlook for 2020 and review progress towards Vision 3x3, the company’s strategic roadmap through 2025 to achieve sustainable growth at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

January 12, 2020
·
9 min read
Drug Development

Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Disease

OC-01 nasal spray showed a statistically significant improvement in Schirmer’s score at Day 84 in both doses tested compared to control

January 12, 2020
·
7 min read
Skyrocketing growth tipped for China Medical industry over next 5 years; Medtec China 2020 upgrades to two halls to meet market needs

According to a forecast from CIConsulting, the revenue of China’s medical equipment and manufacturing industry will reach CNY327.4 billion in 2019, the average annual compound growth rate over the next five years will be about 8.15%, and the market will reach CNY447.9 billion in 2023.

January 12, 2020
·
3 min read
Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC

Innovent Biologics, Inc. jointly announced with Eli Lilly and Company the results of a Phase 3 study in China; the ORIENT-11 trial of Tyvyt® in combination with ALIMTA® and platinum in first-line advanced or recurrent nonsquamous non-small cell lung cancer, without sensitive EGFR mutation or ALK rearrangement, met the predefined primary endpoint of progression-free survival in an interim analysis.

January 12, 2020
·
8 min read